Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
Can-Fite BioPharma (NYSE American: CANF) received a Notice of Allowance from the European Patent Office for its patent application related to the use of the CF602 drug candidate for the treatment of erectile dysfunction in patients such as diabetics. The patent has already been issued in other major markets. Can-Fite's CF602 showed promising results in a diabetic rat model, offering an alternative for non-responders to current ED drugs. The company sees this as a significant addition to their IP estate, positioning CF602 as a potential treatment for sexual dysfunction.
The European Patent Office's allowance for the patent application on CF602's use for erectile dysfunction is a significant milestone for Can-Fite, adding to its intellectual property portfolio and paving the way for further development in the treatment of sexual dysfunction. The promising pre-clinical data and positive results in a diabetic rat model indicate the potential of CF602 as an alternative for patients who do not respond to current ED drugs.
The growing IP estate and positive data surrounding CF602 demonstrate Can-Fite's commitment to addressing high-value indications like erectile dysfunction. The company's focus on innovative drug development and the potential market value of the ED segment further position CF602 as a promising candidate for future therapeutic advancements in sexual dysfunction treatment.
- None.
Insights
From a medical research perspective, the granting of a Notice of Allowance for an erectile dysfunction drug by the European Patent Office represents a significant milestone for Can-Fite BioPharma. The mention of CF602, an allosteric modulator of the A3 adenosine receptor, as a potential new therapy for erectile dysfunction (ED), is of substantial interest due to the limitations of current ED treatments, particularly for diabetic patients.
Phosphodiesterase type 5 (PDE5) inhibitors, while widely used, do not benefit all patients, as indicated by the non-responder rate of 30% to 35%. The pre-clinical studies showing CF602's effects on arterial blood flow and intracavernosal pressure could imply a differentiated mechanism of action from PDE5 inhibitors. This unique interaction with the A3 adenosine receptor might offer not just an alternative treatment, but potentially a more effective one for non-responders and diabetic populations, who are often at higher risk for ED.
Understanding that endothelial nitric oxide synthase is important for erectile function and that vascular endothelial growth factor plays a role in angiogenesis and vascular function, the pre-clinical data suggesting improvements in these areas could indicate a promising therapeutic profile for CF602. However, it is essential to remain cautious until clinical trials in humans confirm these findings and establish safety and efficacy profiles comparable to or better than existing treatments.
Looking at the potential market implications, the erectile dysfunction market is poised for growth, with forecasts reaching around
Considering the unmet need in the ED market, especially among diabetics, Can-Fite's CF602 could capture a significant niche if it proves to be effective post-clinical trials. The CEO's statement on their IP estate's strength and the optimistic pre-clinical data could signal to investors a strategic positioning within the ED drug market. Such positioning might be leveraged in future partnerships or licensing agreements that could boost Can-Fite's market value and bring in revenue streams beyond direct drug sales.
However, without clinical trial data in humans, estimating the exact impact on Can-Fite's financials remains speculative. The overall industry norm suggests a cautious approach until further development stages are completed, but the IP protection in a major market like Europe definitely adds an asset to the company's portfolio.
Patent has already been issued in other major markets including the
PETACH TIKVA,
While oral phosphodiesterase type 5 (PDE5) inhibitors are the current standard of care for erectile dysfunction (ED), with brands including Viagra, Cialis, Levitra, and Stendra, an estimated
Can-Fite recently published an article in Andrologia, suggesting that CF602 could potentially offer an alternative to the current drugs on market. A full erectile recovery was achieved following a single dose of CF602 with restored muscle collagen ratio and endothelial cell function. Can-Fite’s CF602, an allosteric modulator of the A3 adenosine receptor (A3AR), applied topically or orally in a diabetic rat model, resulted in increased arterial blood flow and significant dose-dependent improvements in intracavernosal pressure (ICM), smooth muscle/collagen ratio, vascular endothelial growth factor and endothelial nitric oxide synthase. treatment to PDE5 inhibitors, particularly to PDE5 non-responders and diabetics.
“This additional European patent for erectile dysfunction adds to our growing IP estate for this high-value indication of the CF602 drug candidate. We believe our strong and broad IP, together with the pre-clinical positive data position it as a promising candidate for further development for the treatment of sexual dysfunction,” stated Motti Farbstein, Can-Fite CEO.
The Erectile Dysfunction market is expected to reach approximately
About Namodenoson
Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is currently being evaluated in a pivotal Phase III trial for advanced liver cancer, a Phase IIb trial for the treatment of steatotic liver disease (SLD), and the Company is planning a Phase IIa study in pancreatic cancer. A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent safety profile of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite's cancer and liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment metabolic dysfunction-associated steatohepatitis (MASH), a Phase III pivotal trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to any resurgence of the COVID-19 pandemic and the war between
View source version on businesswire.com: https://www.businesswire.com/news/home/20240506802750/en/
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
Source: Can-Fite BioPharma Ltd.
FAQ
What patent was Can-Fite granted from the European Patent Office?
What are some current standard drugs for erectile dysfunction?
What are the potential benefits of CF602 for ED patients?
What is the expected market size for the Erectile Dysfunction market by 2030?
